The Globe and Mail reports in its Thursday edition that National Bank analyst Zachary Evershed is keeping his "sector perform" call on Neighbourly Pharmacy intact. The Globe's David Leeder writes that Mr. Evershed cut his share target back by 50 cents to $20.50. Analysts on average target the shares at $24.94. The Globe says Mr. Evershed saw Neighbourly Pharmacy's second quarter fiscal 2024 results as "steady." He warns, however, that we are "now back to the waiting game" as there was no update on its proposed move to go private. Mr. Evershed says in a note: "With the stock price pulling back since the transaction announcement, the current price of $17.09 sits at a 16.6-per-cent discount to the offer price. This wide spread likely highlights uncertainties surrounding financing and the announcement of an LOI rather than a definitive agreement, while PCP confirmed that it would not entertain offers from other parties. In light of the uneasy trading picture, we highlight further potential downside risk: using the FY2 FCF yield floor valuation lens we have applied elsewhere in our coverage universe, we calculate Neighbourly's share price would have to fall to $12 to achieve a more defensible 6-per-cent FCF yield."